---
created: 2026-05-10
status: archived-originals
source: planning-router-slimming
---

# Planning Router Original Text Archive — 2026-05-10

This archive preserves the full pre-consolidation text of overlapping planning-router pages before the active KB was slimmed. The active report should use `post-30-day-noninvasive-exam-plan.md` as the Post-Experiment Decision Router; this file is provenance/recovery, not active guidance.


---

## Original `post-30-day-noninvasive-exam-plan.md`

```markdown
---
topic: Post-30-Day Non-Invasive Examination Plan
status: active
decision_target: "Turn the clean-month blood, stool, symptom, BP, and wearable results into the next highest-value examinations before defaulting to endoscopy."
last_updated: 2026-05-04
last_content_change: 2026-05-04
last_evidence_reviewed: 2026-05-04
next_review: 2026-05-26
tags: [thirty-day-experiment, non-invasive, stool-blood, iron, thrombocytosis, bloating, lp(a), bp, ultrasound, endoscopy-threshold]
priority: plan
confidence: medium-high
abstract: >-
  At day 30/31, repeat the paired blood/stool set and consolidate Tracker, stool photos,
  Apple Health, and BP first. Non-invasive escalation should be staged: cardiac risk
  anchoring with BP + echo/CAC; stool/iron/CBC-driven GI decisions; selective abdominal
  ultrasound/FibroScan, H. pylori, celiac, and liver-gallbladder-pancreas checks only when triggered;
  and no routine abdominal CT, full-body CT, or endoscopy for bloating alone. The 2024
  colonoscopy quality gap is now resolved as high-quality/complete, so endoscopy becomes
  hard to avoid mainly if stool blood/RBC persists, iron or hemoglobin drift worsens,
  alarm symptoms appear, or clinician review finds a reason to re-localize the source.
related_topics:
  - thirty-day-experiment.md
  - planned-blood-tests.md
  - whole-profile-seriousness-triage.md
  - occult-stool-blood-workup.md
  - ferritin-iron-workup.md
  - thrombocytosis-lpa-thrombosis.md
  - blood-pressure-profile.md
  - ct-scan-screening.md
  - ldncp-advanced-imaging.md
  - sibo-mmc.md
  - malabsorption-celiac-autoimmune-gastritis.md
open_questions:
  - What do the 2026-05-26/27 repeat blood and stool results show?
  - The 2024 colonoscopy report is now available and documents a complete/high-quality exam (BBPS 9, terminal ileum reached, no polyps/malignancy). If stool blood persists, what source-localization branch does the clinician prefer despite that adequate prior exam?
  - What local facility can do reliable CAC/CCTA, and is baseline echo easiest at RPPH or a heart clinic?
  - If liver risk is revisited after the clean month, does FIB-4 stay clearly low and do AST/ALT/GGT/ALP remain normal?
---

# Post-30-Day Non-Invasive Examination Plan

## Summary

Classification: **INTEGRATE**. This is a router page, not a new lab wish list. The useful move after the clean month is to make the next decisions from paired data, then order examinations only where they change a branch.

The default sequence is:

1. Finish the planned day-30/31 blood + stool repeat.
2. Add low-friction physiology and exam data: 7-day home BP, Apple Health export, focused clinician exam, stool-photo review.
3. Use objective triggers to decide non-invasive add-ons.
4. Escalate to endoscopy only when the stool/iron/alarm branch crosses threshold.

Bloating improvement or persistence should not decide the bleeding branch. Stool blood, stool RBCs, Hb/MCV/RDW, ferritin, TSAT, visible blood, and colonoscopy quality decide that.

## Stage 0 — override rules

These bypass the post-experiment plan:

| Signal | Action |
|---|---|
| Recurrent severe chest/epigastric/upper-abdominal, jaw, shoulder, back, or left-arm/hand symptoms with sweating, dizziness, nausea, dyspnea, palpitations, or unusual weakness | Same-day urgent cardiac rule-out: ECG + high-sensitivity troponin. |
| Visible red/maroon stool, black tarry stool, clots, faintness, tachycardia, rapid weakness, or rapid Hb fall | Urgent GI-bleed assessment. |
| Persistent focal abdominal pain with fever, guarding, vomiting, obstruction symptoms, or worsening severity | Acute abdominal evaluation; imaging becomes clinician-directed. |
| New anemia, Hb drop around 1 g/dL, falling MCV/rising RDW, ferritin moving toward <45-50, persistent TSAT <20%, repeat stool blood/RBC positive | Move from monitoring to GI-source planning. |
| Platelets rising substantially, platelets persistently >=450 without a reactive explanation, WBC remains high with abnormal differential, smear abnormality, splenomegaly, night sweats, weight loss | Smear/hematology branch. |

Red-flag wording is summarized from [Whole-Profile Seriousness Triage](#sec-whole-profile-triage) and [Recurrence Action Plan](#sec-recurrence-action); keep those pages as the canonical emergency-routing owners.

## Stage 1 — day-30/31 core dataset

Do this first, because it determines whether examinations are useful or noisy.

| Bucket | Core data | Decision use |
|---|---|---|
| Blood-loss / iron | CBC/Hg with indices and platelets, ferritin, serum iron, TIBC or transferrin, derived/reported TSAT, reticulocyte | Decides whether occult-blood signal is biologically active. |
| Stool blood | FOB + Stool Direct Exam; ideally 2-3 specimens if logistics allow, at minimum one paired end-experiment set | Decides whether stool-blood branch cleared or persists. |
| Inflammation / reactive tone | CRP hs or CRP, ESR, fibrinogen, CBC differential if available | Context for WBC/platelets and inflammatory branch. |
| Metabolic paired data | Fasting glucose + fasting insulin if preserving the day-0 comparison | Optional paired physiology; not a GI escalation driver. |
| Logs | Tracker meals, symptoms, circumference, exercise, stool photos; Apple Health export | Separates symptom burden from objective blood/stool risk. |
| BP | 7-day home BP protocol, average days 2-7 preferred | Major missing CVD risk variable; useful even if GI branch calms. |

Biomed tariff cross-check, 2026-05-03: the repeat blood/stool core is locally cheap. Core repeat including fasting glucose/insulin is about **$50.75**; without glucose/insulin about **$37.75**. Public tariff confirms CBC/Hg, reticulocyte, ferritin, serum iron, TIBC, FOB, Stool Direct Exam, fibrinogen, CRP hs, ESR, fasting glucose, and fasting insulin. Prices change, so recheck before ordering.

## Stage 2 — result branches

| Result pattern after clean month | Meaning | Next examination path |
|---|---|---|
| FOB/direct stool exam negative, Hb/MCV/RDW stable, ferritin stable or rising, TSAT >=20-ish, WBC/platelets improve | GI bleeding branch cools; clean month likely improved noise | No default endoscopy. Continue monitoring; shift attention to BP/cardiac imaging and symptom management. |
| Stool blood/RBC persists but Hb/ferritin/TSAT are stable | Occult blood remains unresolved even if not acute | The 2024 colonoscopy quality gap is resolved as reassuring, so do not repeat colonoscopy automatically. If positivity repeats, GI-source discussion is still the next step; clinician decides repeat lower-GI/anorectal review vs upper-GI branch based on pattern. |
| Ferritin falls toward <45-50, TSAT remains <20, MCV/RDW drifts, or Hb drops | Possible ongoing loss or iron restriction | GI-source planning becomes stronger; endoscopy threshold lowers substantially. |
| Platelets remain >=450 or WBC remains high | Reactive explanation still possible, but not closed | CBC differential + peripheral smear if available; interpret with iron/stool/inflammation. JAK2/CALR/MPL only if persistent unexplained after reactive cleanup or if clinician wants early uncertainty reduction. |
| Bloating/distension persists but stool/iron/Hb are clean | Symptom branch, not bleeding proof | Meal-spacing/diet/SIBO-SUDD clinician logic; no routine CT/endoscopy solely for bloating unless alarm features or recent worsening. |
| BP average elevated or morning BP high | CVD risk branch becomes actionable | Clinician discussion, ABPM if uncertain, and stronger cardiac-prevention prioritization. |
| Apple Health shows recovery with abstinence | Exposure-response signal | Reinforces smoking/alcohol abstinence; not a diagnostic substitute for blood/stool/cardiac results. |

## Non-invasive examinations: do now, trigger, defer

### Do now / high-value baseline

| Examination | Why now | Notes |
|---|---|---|
| Focused clinician review and physical exam | Cheapest way to check abdomen, rectal/anorectal clues, lymph nodes, spleen/liver, cardiac exam, BP technique, and alarm symptoms | Bring the one-page timeline, repeat labs, stool results, stool photos if useful, and the 2024 colonoscopy report. |
| 7-day home BP profile | BP is the biggest missing cardiovascular risk variable | Use validated upper-arm cuff; morning/evening duplicate readings; average days 2-7. |
| Baseline transthoracic echocardiogram | Lp(a) is causally linked to aortic-valve stenosis; CAC/CCTA do not assess valve hemodynamics | Can be done independently of GI results. |
| CAC score as low-friction coronary anchor | Very high Lp(a) + smoking history means blood lipids alone do not show plaque burden | If CAC >0, cardiology/prevention escalation and possible CCTA become more concrete. |
| CCTA only if symptoms recur, CAC is positive/meaningful, or cardiology wants direct plaque/anatomy detail | CCTA shows stenosis and non-calcified/high-risk plaque features that CAC misses | Prefer a center that can report non-calcified plaque and high-risk features; AI-QCT is useful only if report contents are real. |

### Triggered non-invasive add-ons

| Add-on | Trigger | Why / boundary |
|---|---|---|
| Repeat calprotectin | New persistent diarrhea, inflammatory symptoms, fever/pain flare, or clinician wants IBD/diverticular-inflammation context | Normal calprotectin does not clear bleeding; repeat is not needed just because FOB was positive. |
| H. pylori stool antigen or urea breath test | Dyspepsia/epigastric symptoms, persistent iron-loss branch, ulcer concern, or before any future aspirin/NSAID-risk discussion | Biomed lists stool antigen. If positive, treat and confirm eradication after therapy. |
| Celiac/malabsorption screen | Persistent unexplained iron/TSAT problem, chronic non-bloody diarrhea/weight loss, or bloating plus objective malabsorption signals | Use [Celiac + Autoimmune Gastritis + Malabsorption Screen](#sec-malabsorption-screen): first-line is tTG-IgA while eating gluten; Biomed public tariff did not show tTG/DGP/EMA/HLA-DQ2/DQ8 on 2026-05-03, so ask by exact send-out name or use another lab/hospital. |
| Liver/gallbladder/pancreas blood checks: AST/ALT, ALP, GGT, bilirubin, albumin/PT, lipase ± amylase | RUQ/epigastric pain, fatty-food pattern, jaundice/dark urine, pale stool, steatorrhea, recurrent severe upper-abdominal symptoms, abnormal clinician exam, or a deliberate MASLD/fibrosis recheck | Cheap, but not a routine explanation for pure lower bloating. Biomed's liver-function panel is a low-friction lab route. |
| Abdominal ultrasound | Abnormal liver/gallbladder labs, RUQ/epigastric pattern, palpable organ enlargement/mass, unexplained weight loss, persistent focal pain, or clinician concern | Reasonable before CT when hepatobiliary/organ-size questions exist; can detect steatosis/gallbladder findings but cannot stage fibrosis well and is low yield for uncomplicated bloating alone. |
| FibroScan / transient elastography | FIB-4 >=1.3, abnormal AST/ALT/GGT/ALP, ultrasound steatosis, diabetes/obesity or multiple metabolic-risk traits, strong clinician concern, or RPPH package used opportunistically | Use as second-line fibrosis risk stratification. Guideline-style thresholds: VCTE liver stiffness <8 kPa usually lowers advanced-fibrosis concern; 8-12 kPa is indeterminate; >=12 kPa or FIB-4 >2.67 pushes specialist review. |
| True serum protein electrophoresis | If IgA branch still needs band-pattern clarification or total protein/globulin/renal/anemia/red flags change | Biomed lists Protein Electrophoresis / Electrophoresis-Protein; do not confuse it with hemoglobin electrophoresis. |
| PSA total + free PSA | If repeating PSA under standardized conditions or PSA remains/rises near threshold | Avoid ejaculation/cycling and infection/prostatitis confounding before draw. |
| SIBO hydrogen + methane breath testing | Bloating remains disruptive after clean month and result would change treatment | Phnom Penh access unconfirmed; ask specifically for hydrogen + methane and glucose/lactulose substrate. |

### Defer by default

| Examination | Defer because |
|---|---|
| Routine abdominal CT for bloating/occult blood | Low value without acute pain, fever, obstruction, mass, weight loss, abnormal exam/labs, or clinician-directed structural concern. |
| Full-body screening CT | Incidentaloma/radiation burden and no mortality-benefit rationale. |
| LDCT lung screening | Only if careful smoking reconstruction reaches USPSTF-style >=20 pack-years and current/recent smoker criteria, or a clinician has symptom-based reason. |
| Capsule endoscopy | Usually after adequate colonoscopy + gastroscopy are unrevealing and occult bleeding/IDA persists. |
| Broad microbiome testing, exotic inflammation panels, shotgun autoimmune panels | Too many false trails unless the repeat objective pattern creates a target. |
| Immunofixation/free light chains | Second-line if true SPEP is suspicious or renal/anemia/calcium/bone/constitutional red flags appear. |

## MASLD / liver-fibrosis hidden-risk rule

Classification: **INTEGRATE / mostly DROP unless triggered**. The remaining queue item asked whether silent MASLD or liver fibrosis could be an inflammation/CVD amplifier despite good insulin sensitivity. Current personal data make advanced fibrosis low probability: AST 17, ALT 12, GGT 27, bilirubin normal, albumin high-normal, HbA1c 5.1%, fasting insulin 4.4 with HOMA-IR about 1.08, triglycerides 1.29 mmol/L, and platelets are high rather than low. Using the April 2026 values, **FIB-4 is about 0.51**, well below the usual <1.3 low-risk cutoff. Similar recent FIB-4 estimates also stay around 0.47-0.51.

The practical rule is:

| Pattern | Interpretation | Action |
|---|---|---|
| FIB-4 <1.3, AST/ALT/GGT/ALP/bilirubin normal, no ultrasound steatosis, no diabetes/obesity/multiple metabolic-risk traits | Advanced liver fibrosis unlikely; liver is not the leading explanation for ESR/IgA/WBC/platelets/CVD risk | Drop MASLD as an active workup branch. Recheck ordinary liver enzymes with future panels or after alcohol relapse, but do not chase FibroScan by default. |
| Ultrasound reports steatosis, FIB-4 rises >=1.3, AST/ALT/GGT/ALP become persistently abnormal, triglycerides/glucose/BP/waist become metabolic-syndrome-like, or clinician exam suggests liver disease | MASLD/MetALD branch becomes plausible enough to quantify fibrosis | Do FibroScan/VCTE if accessible; use <8 kPa as reassuring for advanced fibrosis, 8-12 kPa as repeat/clinician-indeterminate, and >=12 kPa as hepatology-level concern. |
| FIB-4 >2.67, VCTE >=12 kPa, low platelets, high bilirubin/INR, low albumin, splenomegaly/ascites, or imaging signs of chronic liver disease | Possible advanced fibrosis/cirrhosis branch | Specialist review rather than self-directed supplement or diet experiments. |

Why this stays in the router rather than a standalone topic: MASLD can be an independent cardiovascular-risk context in populations, and lean/non-obese disease exists, but for this profile the current objective markers point elsewhere. The higher-yield branches remain BP, Lp(a)-plaque/valve imaging, stool-blood/iron, CBC/smear, and smoking/alcohol abstinence. Liver testing becomes useful if it produces a concrete fibrosis-stage decision, not as a vague explanation for every inflammatory marker.

## When endoscopy becomes hard to avoid

Endoscopy is not the default for symptom anxiety or bloating alone. It becomes hard to avoid if one or more objective triggers persist:

- repeat FOB or stool RBC remains positive, especially on more than one specimen
- Hb drops around 1 g/dL, falls below range, MCV drifts down, or RDW rises
- ferritin falls toward <45-50 or TSAT remains <20 despite clean month and iron-focused diet/timing
- visible blood, melena, recurrent severe epigastric pain/dyspepsia, weight loss, nocturnal symptoms, progressive bowel-habit change, or persistent focal pain appears
- a clinician finds abnormal exam findings or judges that persistent blood needs renewed source localization despite the complete/high-quality 2024 colonoscopy

Default sequence if this branch opens: GI-source review first. Because the 2024 colonoscopy was complete/high-quality, repeat colonoscopy is a clinician judgment rather than a reflex, but persistent stool blood in a 51-year-old male with prior hematochezia/diverticula still keeps lower-GI/anorectal review near the front. Gastroscopy moves earlier with melena, epigastric/ulcer symptoms, or iron-deficiency anemia; capsule comes after adequate upper + lower endoscopy if bleeding/IDA persists.

## Practical end-of-month order sheet

Do not order all triggered items. Start with the core set and add only triggered items.

| Category | Practical order |
|---|---|
| Core repeat | CBC/Hg, reticulocyte, ferritin, serum iron, TIBC or transferrin/TSAT, CRP hs/CRP, ESR, fibrinogen, FOB, Stool Direct Exam, fasting glucose + insulin if preserving the paired baseline. |
| If stool/iron branch persists | 2024 colonoscopy is already verified high-quality; bring the report anyway. Consider H. pylori stool antigen and celiac serology if symptoms/iron pattern fit; GI-source discussion if positivity or iron drift persists, with clinician deciding lower-GI/anorectal vs upper-GI sequence. |
| If CBC branch persists | CBC differential and smear; then mutation/hematology logic only if persistent unexplained. |
| If upper-abdominal/liver-gallbladder/MASLD branch appears | AST/ALT, ALP, GGT, bilirubin, albumin/PT, lipase ± amylase; abdominal ultrasound if labs/symptoms/exam point there; FibroScan only if FIB-4/labs/ultrasound/metabolic risk crosses threshold or RPPH package is deliberately chosen. |
| If cardiac prevention branch | 7-day BP, echo, CAC; CCTA if symptoms/CAC/specialist threshold. |
| If symptom branch only | Continue Tracker/circumference/stool-photo review; consider GI consultation for SUDD/SIBO/IBS strategy rather than broad imaging. |

## Research trace

- Research date: 2026-05-03; MASLD hidden-risk refresh added 2026-05-04.
- Classification: **INTEGRATE**. The queue item needed a new post-experiment router because no existing owner combined stool/iron/CBC, symptom, cardiac, BP, Apple Health, local-lab, and endoscopy-threshold logic.
- Personal context reviewed: refreshed cloud doc; research queue; whole-profile triage; 30-day experiment; day-0 Biomed plan; occult stool blood; ferritin/iron; thrombocytosis; blood pressure; LDNCP/CAC/CCTA; CT screening; SIBO/MMC; elevated IgA; B12; PSA; Phnom Penh medical access.
- Local logistics checked: Biomed public tariff HTML on 2026-05-03 for CBC/Hg, reticulocyte, ferritin, serum iron, TIBC, transferrin saturation, FOB, Stool Direct Exam, calprotectin, H. pylori stool antigen, fibrinogen, CRP hs, ESR, fasting insulin/glucose, protein electrophoresis, PSA, liver/pancreas enzymes. No public tTG/endomysial/gliadin listing found in the page HTML.
- Evidence anchors: AGA IDA guideline and non-invasive H. pylori/celiac logic after IDA evaluation (AGA 2020; PMID: 32810434); BSG IDA/non-anaemic iron deficiency framing (PMID: 34497146; PMID: 35002031); FOB/FIT limitations and positive-stool-test colonoscopy logic (PMID: 40675631; USPSTF CRC/FIT guidance as background); AGA bloating/distension CPU selective testing/imaging rule (Gastroenterology 2023); AHA/ACC chest pain guideline (PMID: 34709879); EAS Lp(a) ASCVD/aortic-stenosis consensus (PMID: 36036785); thrombocytosis investigation review (PMID: 38375212); ACG celiac guideline summary (Am J Gastroenterol 2023; AAFP 2024); ACG H. pylori 2024 guideline highlights; USPSTF LDCT lung-screening criteria (2021); ESC 2024 BP guideline commentary and home-BP emphasis.
- Stop condition: a staged decision tree that says what to do now, what to trigger, what to defer, and exactly when endoscopy stops being optional.
- MASLD refresh anchors: AASLD 2023 NAFLD practice guidance and EASL-EASD-EASO 2024 MASLD guideline support stepwise FIB-4 then elastography case-finding in people with cardiometabolic risk factors, abnormal liver enzymes, or steatosis, especially T2D/obesity (PMIDs: 36727674, 38851997). AGA pathway uses FIB-4 <1.3 and VCTE <8 kPa as low-risk anchors, while FIB-4 >2.67 plus VCTE >=12 kPa is advanced-fibrosis concern; broad use can over-test low-risk people (PMID: 35989502). Lean/non-obese NAFLD exists and has outcomes, but it is not a reason to bypass the low FIB-4/normal-enzyme drop rule without steatosis or metabolic triggers (PMID: 32413340). NAFLD/MAFLD cardiovascular associations are observational and support risk-factor control rather than liver testing as a substitute for BP/Lp(a)/imaging work (PMIDs: 27212244, 36187109).
- Local logistics: RPPH publicly lists a Healthy Liver Screening Package poster with FibroScan plus upper-abdominal ultrasound. The poster offer date expired on 2025-12-31; use this only as a service lead until phone confirmation of current availability, kPa/CAP reporting, and price. Biomed publicly lists a $12.50 Liver Functions Test panel including albumin, prothrombin time, ALP, bilirubin, globulin, total protein, AST/ALT, and GGT.

```


---

## Original `post-experiment-treatment-priority-plan.md`

```markdown
---
topic: Post-Experiment Treatment-Priority Plan
status: active
decision_target: "After the clean-month dataset, rank management changes by expected outcome benefit, safety, feasibility, and whether the result pattern actually justifies them."
last_content_change: 2026-05-03
last_evidence_reviewed: 2026-05-03
next_review: 2026-05-26
tags: [thirty-day-experiment, treatment-priority, lp(a), blood-pressure, smoking, alcohol, occult-blood, iron, bloating, inflammation, anxiety]
priority: plan
confidence: medium-high
abstract: >-
  After the 30-day experiment, treatment priority should be result-triggered rather than anxiety-triggered. The likely highest-yield moves are durable smoking/alcohol abstinence, BP measurement/control, ApoB/LDL and imaging-guided cardiovascular prevention, then stool-blood/iron and CBC branches if objective signals persist. Bloating/SUDD, skin control, and fear-management matter for quality of life, but they should not outrank plaque/BP/smoking or persistent stool-blood/iron evidence.
related_topics:
  - thirty-day-experiment.md
  - post-30-day-noninvasive-exam-plan.md
  - whole-profile-seriousness-triage.md
  - prevention-status-cvd-burden.md
  - blood-pressure-profile.md
  - smoking-alcohol-relapse-risk.md
  - occult-stool-blood-workup.md
  - ferritin-iron-workup.md
  - thrombocytosis-lpa-thrombosis.md
  - sibo-mmc.md
open_questions:
  - What do the day-30/31 blood, stool, BP, Apple Health, and symptom-log results show?
  - Does imaging document plaque or aortic-valve disease?
  - Does stool blood clear, and do platelets/WBC improve after exposure cleanup?
---

# Post-Experiment Treatment-Priority Plan

## Summary

Classification: **INTEGRATE**. This is the treatment companion to the post-30-day examination router. The core rule is: **treat what changes outcomes first; treat symptoms second; avoid invasive or drug-heavy branches unless objective triggers justify them.**

The expected priority order after the clean month is:

1. keep smoking and alcohol at zero, or turn relapse into a support plan rather than a moral failure
2. complete cardiovascular risk anchoring: 7-day BP, echo/CAC or CCTA logic, cardiology discussion if plaque/valve/BP findings appear
3. tighten ApoB/LDL/BP treatment only according to actual risk tier, not Lp(a) panic alone
4. follow stool-blood/iron and CBC branches if repeat results stay abnormal
5. manage bloating/SUDD with low-risk symptom strategies before antibiotics/prokinetics/procedures
6. control skin/oral/infection sources if they are visibly active or markers stay inflammatory
7. use structured fear/anxiety tools when monitoring itself starts damaging daily life

## Decision inputs first

Do not rank treatments from one symptom day. Rank them from this dataset:

| Input | What it decides |
|---|---|
| 7-day home BP average | Whether BP control becomes a top cardiovascular treatment target. |
| Echo/CAC/CCTA path | Whether prevention stays high-risk primary prevention or becomes plaque/valve-documented disease management. |
| CBC with differential, platelets, smear if triggered | Whether thrombocytosis/WBC looks reactive or needs hematology-style testing. |
| Ferritin, iron/TIBC/TSAT, Hb/MCV/RDW, reticulocyte | Whether iron repletion is a bridge or whether source investigation dominates. |
| FOB + Stool Direct Exam, ideally repeated if feasible | Whether the occult-blood branch has cleared or persists. |
| Tracker, stool photos, circumference, Apple Health | Symptom burden, exposure response, sleep/recovery, and bloating branch. |

## Treatment hierarchy

| Priority | Treatment / management move | Who leads | Use it when | Why it ranks here |
|---|---|---|---|---|
| 0 | Red-flag response: ECG/troponin for recurrent convincing cardiac-type symptoms; urgent GI assessment for active bleeding | Clinician / emergency | Severe chest/epigastric/arm/autonomic recurrence, visible major bleeding, melena, faintness, rapid weakness | Time-sensitive harm prevention outranks all plans. |
| 1 | Durable smoking abstinence | Self + cessation support if needed | Always, especially if any relapse occurs | Highest modifiable ASCVD/thrombotic lever in a very high Lp(a) profile; WBC/oxidative markers can improve after cessation. |
| 2 | Alcohol abstinence or strict long-term low-use rule | Self; clinician if dependence pattern appears | Always while stool-blood/iron/gut/BP questions are live | Heavy alcohol reduction lowers BP most in heavier drinkers and removes gut, sleep, adherence, and arrhythmia noise. |
| 3 | BP diagnosis and control | Self measurement first; clinician if elevated | Elevated 7-day home average, morning hypertension, or high clinic confirmation | BP lowering has strong outcome evidence; in high Lp(a), it is one of the few large controllable risk drivers. |
| 4 | Lipid / plaque-prevention escalation | Clinician / cardiology | CAC >0, CCTA plaque, aortic-valve disease, or clinician-selected lower target | Current ApoB is already good, but documented plaque/valve disease makes ezetimibe/PCSK9-style escalation more rational. |
| 5 | Stool-blood / iron source plan | GI clinician; self only for logging and safe prep | Repeat FOB/RBC positive, ferritin falls toward <45-50, TSAT stays <20, Hb/MCV/RDW worsens, visible blood, or colonoscopy quality uncertain | Persistent occult blood in a 51-year-old male should not be hidden by symptom improvement or iron pills. |
| 6 | Iron repletion bridge | Clinician or cautious self-management if agreed | Falling ferritin/TSAT, depletion symptoms, or clinician wants repletion while source is clarified | Useful for symptoms and reserves, but not a substitute for source workup if stool blood persists. |
| 7 | CBC / platelet-WBC pathway | Clinician | Platelets remain >=450, WBC remains high, smear abnormal, or reactive causes fade | Reactive remains plausible; persistence triggers smear, then JAK2/CALR/MPL logic rather than reassurance. |
| 8 | Bloating / SUDD / SIBO symptom strategy | Self first; GI if disruptive | Stool/iron branch is clean or separately handled, but bloating remains life-limiting | Quality-of-life target: meal spacing, soluble fiber titration, modified low-FODMAP trial, breath-test/clinician logic if needed. |
| 9 | Skin, dental, infection, oral-health cleanup | Dermatology/dentist as needed | Active eczema/psoriasis, gum bleeding, dental infection, persistent inflammatory markers | Plausible inflammatory contributors; valuable, but usually not as outcome-dominant as smoking/BP/plaque or stool blood. |
| 10 | Fear/anxiety-management support | Self + CBT-style tools; therapist if intrusive | Monitoring creates avoidance, rumination, repeated reassurance seeking, or lifestyle restriction beyond the data | Improves quality of life and decision quality; not a substitute for objective red-flag rules. |

Red-flag wording is summarized from [Whole-Profile Seriousness Triage](#sec-whole-profile-triage) and [Recurrence Action Plan](#sec-recurrence-action); keep those pages as the canonical emergency-routing owners.

## Safe self-management trials

These are reasonable without waiting for specialist permission, as long as red flags are absent and objective branches are not ignored:

- keep zero smoking and zero alcohol; log slips and use a 72-hour confounding window
- continue atorvastatin as prescribed; do not add aspirin/NSAIDs for prevention while stool-blood risk is live
- complete the home BP protocol with a validated upper-arm cuff before arguing about BP treatment
- keep meal spacing / no caloric snacks when practical; compare bloating score and abdomen circumference
- use vegetarian iron meals with vitamin C and keep coffee/tea away from iron-focused meals
- titrate fiber gently; prefer soluble/gradual changes over sudden high-load experiments
- keep exercise regular but not heroic: enough for BP, sleep, mood, insulin sensitivity, and inflammation; avoid treating maximal exertion as a gut test
- use a red-flag checklist and scheduled review points instead of reinterpreting weak symptoms daily

## Clinician-led decisions

These should not be self-prescribed from internet logic:

- starting antihypertensive medication if home/clinic BP confirms hypertension
- adding ezetimibe or PCSK9 inhibitor, especially if imaging documents plaque or aortic-valve disease
- deciding whether persistent stool blood needs colonoscopy/gastroscopy and in what order
- starting antibiotic/prokinetic SIBO/SUDD regimens such as rifaximin, neomycin, or prucalopride
- JAK2/CALR/MPL, BCR-ABL1, or broader hematology workup
- systemic eczema/psoriasis therapy beyond ordinary topical maintenance
- aspirin or other antiplatelet therapy if coronary disease is later documented; this must include GI bleeding risk

## What would count as success

| Branch | Good signal | If not achieved |
|---|---|---|
| Exposure cleanup | No smoking/alcohol; resting HR/sleep/BP/gut logs improve | Treat relapse prevention as the first treatment problem. |
| Cardiovascular | Home BP normal, imaging low burden, ApoB/LDL accepted by clinician | Control BP; discuss lower LDL/ApoB target and non-statin therapy if plaque/valve disease appears. |
| GI blood / iron | FOB/RBC clear; Hb/MCV stable; ferritin/TSAT stable or rising | GI-source planning moves up; iron alone is not enough. |
| CBC/inflammation | WBC, platelets, fibrinogen, CRP/ESR improve | Add differential/smear; consider molecular testing if persistent unexplained. |
| Bloating/SUDD | Lower bloating score, smaller circumference spikes, better stool photos, less urgency | GI symptom branch remains active; consider celiac/H. pylori/SIBO or diet trials by trigger, not shotgun testing. |
| Skin/fear burden | Fewer flares, less itch/sleep disruption, less threat-monitoring | Dermatology/dental/CBT-style support becomes more worthwhile. |

## Evidence / context

The evidence is strongest for cardiovascular risk-factor treatment, not for exotic inflammation chasing. Lp(a) is causal for ASCVD and aortic stenosis, but current management before Lp(a)-specific drug outcomes is early intensive control of other risk factors. BP lowering reduces major cardiovascular events by about 20% per 10 mmHg systolic reduction in large trial meta-analysis. LDL lowering reduces major vascular events by about one fifth per 1 mmol/L LDL-C reduction, with more intensive lowering giving further benefit when risk is high enough. Smoking cessation improves oxidative/WBC inflammatory signals despite possible weight gain, and no safe smoking level should be assumed. Alcohol reduction lowers BP most clearly in heavier drinkers and is also a gut/sleep/adherence intervention here.

GI and bloating evidence is more trigger-dependent. AGA IDA guidance supports ferritin <45 ng/mL as the anemia cutoff and bidirectional endoscopy for men with iron-deficiency anemia, but this profile is currently non-anemic; persistent positive stool blood, falling iron markers, or uncertain colonoscopy quality are what raise the invasive threshold. AGA bloating guidance supports selective testing rather than routine imaging; SIBO/breath testing and diet trials belong to the symptom branch, not the bleeding branch. CBT and internet/mobile CBT have randomized-trial meta-analysis support for anxiety/depression and distress in chronic disease; their role here is better monitoring behavior and quality of life, not pretending symptoms are imaginary.

## Research trace

- Research date: 2026-05-03.
- Classification: **INTEGRATE**. The active queue item needed a standalone treatment router because the existing post-30-day page owns examinations, not treatment prioritization.
- Personal context reviewed: refreshed cloud doc, current queue/index, whole-profile triage, 30-day experiment, post-30-day exam plan, smoking/alcohol relapse, prevention status, occult stool blood, ferritin/iron, thrombocytosis, inflammatory-thrombotic axis, and SIBO/MMC topics.
- Evidence anchors: EAS Lp(a) consensus (PMID: 36036785); BP-lowering meta-analysis (PMID: 26724178); LDL-lowering CTT meta-analysis (PMID: 21067804); smoking cessation/inflammatory markers (PMIDs: 27932354, 15974805); alcohol reduction/BP meta-analysis (PMID: 29253389); AGA IDA guideline summary (PMID: 32810434); AGA bloating/distension CPU (PMID: 37452811); exercise and hsCRP meta-analysis (PMID: 26916454); chronic-disease CBT meta-analyses (PMIDs: 37865080, 37117458).
- Stop condition: a branch-ranked treatment plan that separates clinician-led decisions from safe self-management and prevents symptom anxiety from outranking objective risk branches.

```


---

## Original `personal-knowledge-widening-roadmap.md`

```markdown
---
topic: Personal Knowledge-Widening Test and Experiment Roadmap
tags: [planning, tests, experiments, personal-baseline, blood-tests, imaging, home-monitoring, logistics]
priority: plan
last_updated: 2026-05-10
confidence: medium-high
abstract: >-
  This roadmap ranks tests and experiments by how much genuinely new personal information they can add, not by curiosity or repeat-monitoring value. Highest yield now is physiology and burden mapping that has never been measured well: 7-day BP, echo/CAC or CCTA pathway, true SPEP for the unresolved IgA pattern, and triggered platelet/iron/stool branches. A one-off 24-hour fast is only a low-priority gut/motility signal test; 48-72-hour fasting is deferred because it adds more interpretation noise than decision value during the clean month. Low-yield novelty tests are explicitly parked so the KB does not drift into “test everything”.
related_topics:
  - blood-pressure-profile.md
  - ldncp-advanced-imaging.md
  - ct-scan-screening.md
  - elevated-iga-workup.md
  - thrombocytosis-lpa-thrombosis.md
  - post-30-day-noninvasive-exam-plan.md
open_questions:
  - Which highest-yield knowledge gap should be closed first after the clean-month repeat panel?
  - Can RPPH provide a clear CAC/CCTA/echo package with plaque and valve reporting details?
  - Does the end-of-experiment dataset make any conditional branches worth activating?
---

# Personal Knowledge-Widening Test and Experiment Roadmap

## Summary

Classification: **INTEGRATE**. The useful concept is not “more tests”; it is a ranked map of tests or experiments that would reveal a new layer of personal biology, anatomy, physiology, or risk. Lp(a) was the prototype: one measurement permanently changed the risk model. Future items should be judged by the same standard.

A test earns a high place here if it answers at least one of these:

1. **A hidden high-impact variable:** BP, plaque burden, valve status, clonal vs reactive blood-cell signal.
2. **A decision boundary:** whether to intensify prevention, see cardiology/GI/hematology/urology, or stop chasing a branch.
3. **A stable baseline:** a one-time or rarely repeated measurement that makes future changes interpretable.
4. **A clean experiment signal:** a behavioral intervention that can be measured against before/after logs or labs.

Routine repeats are not listed as “knowledge-widening” unless they trigger a new branch. The planned day-30/31 repeat panel remains the first checkpoint; this roadmap decides what to add after that, not what to shotgun now.

## Priority 1 — highest personal-information yield

| Item | New knowledge gained | Practical next step | Decision impact |
|---|---|---|---|
| **7-day home blood-pressure profile** | First reliable BP phenotype: normal, elevated, masked, morning-heavy, stress/noise-linked. | Do the existing 7-day protocol with a validated upper-arm cuff; average days 2-7. | If elevated, BP control becomes a core high-Lp(a) risk intervention. If normal during the clean month, a major risk amplifier is partly cleared. |
| **Baseline echocardiogram** | Aortic valve and LV baseline, which CAC/CCTA cannot provide. | RPPH or cardiac clinic echo; ask for aortic valve sclerosis/stenosis, gradients, valve calcification note, LVH, EF, atrial size. | Very high Lp(a) makes valve status a real unknown. A normal baseline is useful; abnormalities change cardiology follow-up. |
| **CAC score; CCTA only if it will change management** | Actual coronary plaque burden instead of blood-marker inference. CCTA adds non-calcified plaque/anatomy if available and justified. | Confirm RPPH package: CAC vs contrast CCTA vs both, ECG gating, Agatston, stenosis, non-calcified/high-risk plaque fields, dose, price. | CAC >0 or meaningful plaque changes prevention intensity. CAC=0 is reassuring but not a full high-Lp(a) all-clear. |
| **True serum protein electrophoresis (SPEP)** | Whether high IgA is broad/reactive or narrow/monoclonal-looking. | Biomed: **Electrophoresis-Protein / Protein Electrophoresis**, serum, $25, 3-5 days. Avoid hemoglobin electrophoresis. | A clean/polyclonal SPEP cools the IgA branch. Suspicious SPEP triggers immunofixation/FLC/hematology logic. |

## Priority 2 — activate if the clean-month repeat keeps the branch open

| Item | Trigger | New knowledge gained | Local practicality |
|---|---|---|---|
| **CBC with differential + peripheral smear** | Platelets remain >=450, WBC remains high, or differential looks abnormal. | Reactive pattern vs abnormal morphology/left shift/basophilia/platelet morphology. | CBC is cheap at Biomed; smear availability should be confirmed because the tariff clearly lists malaria blood smear but not a general hematology smear row. |
| **JAK2 V617F** | Persistent unexplained thrombocytosis after iron/stool/inflammation cleanup, or clinician wants earlier uncertainty reduction. | Clonal MPN/CHIP-like signal vs reactive thrombocytosis. | Biomed now lists **Janus Kinase 2 (JAK2 V617F)**, EDTA blood, $150, 5-7 days. CALR/MPL were not found on the public tariff. |
| **Repeat stool-blood set on 2-3 specimens** | End-of-month FOB/direct exam remains positive or iron markers drift. | Whether occult blood is persistent or a one-sample/local-assay signal. | Biomed: FOB $7.50; Stool Direct Exam $2. FIT not publicly listed. This is branch resolution, not novelty for its own sake. |
| **Celiac serology by exact send-out name** | Persistent iron/TSAT problem, chronic non-bloody diarrhea/weight loss, or bloating with malabsorption clues while eating gluten. | Whether gluten/celiac disease is a hidden malabsorption driver. | Biomed public tariff did not show tTG-IgA/DGP/EMA/HLA-DQ2/DQ8; ask exact names or use hospital/send-out. Old 2015 tTG/DGP were negative, so this is not first-line unless triggered. |
| **H. pylori stool antigen or breath test** | Dyspepsia/epigastric symptoms, persistent iron-loss branch, ulcer concern, or before future aspirin/NSAID-risk discussion. | Treatable upper-GI source/noise. | Biomed stool antigen is $15; prior stool antigen was non-reactive in 2025-12, so repeat only if branch changes. |

## Priority 3 — useful one-time baselines, but not urgent

| Item | New knowledge gained | When it is worth doing | Local practicality |
|---|---|---|---|
| **Urine albumin-creatinine ratio** | Microvascular/kidney-risk layer not captured by dipstick urine. | Good one-time baseline with high Lp(a), BP uncertainty, and vascular-risk mapping. | Biomed has Albumin Micro/Urine $10 and Creatinine/Urine $2.50; ask whether they report ACR directly or can calculate from same urine. |
| **Cystatin C** | Creatinine-independent kidney filtration estimate and risk staging. | Useful if wanting a better renal baseline before contrast imaging, BP decisions, or long-term vascular-risk tracking. | Biomed lists Cystatin C $15, 3-5 days. |
| **Free PSA with standardized repeat PSA** | Clarifies whether PSA 2.85 is transient vs persistent risk signal. | Only if repeating PSA under clean conditions; avoid ejaculation/cycling/prostate irritation/infection confounding first. | Biomed: PSA Total $10, Free PSA $15. |
| **Hepatitis B triple-panel / immunity check** | Confirms current HBV infection status, past exposure, and vaccine immunity after prior vaccination and historical anti-HBs negativity. | Reasonable travel-health cleanup, especially if status has not been checked after vaccination. | Biomed has HBsAg, anti-HBs quantitative, anti-HBc total. This is useful logistics, not a core current-health mystery. |
| **NT-proBNP** | Cardiac wall-stress baseline. | Optional if dyspnea, edema, exercise intolerance, abnormal echo, or clinician wants cardiac-strain context. | Biomed: NT-proBNP / Pro-BNP $40. Low yield if asymptomatic with a normal echo. |
| **TPO Ab + anti-thyroglobulin** | Autoimmune thyroid tendency. | Only if TSH rises again or symptoms/thyroid exam make it relevant. | Biomed: TPO Ab $15; anti-thyroglobulin $16.25. TSH normalized, so this is parked. |

## Priority 4 — experiments that widen interpretation, not just lab data

| Experiment | What it can teach | Design rule |
|---|---|---|
| **Clean-month paired analysis** | Exposure response of alcohol/smoking/coffee/meal timing against BP, HR/HRV, sleep, gut symptoms, stool photos, circumference, CBC/iron/inflammation. | Do not over-interpret one marker. Compare clusters: symptoms + logs + stool/blood + BP/wearables. |
| **Meal-spacing / no-snacking SIBO-MMC trial** | Whether post-prandial bloating responds to longer fasting gaps and fewer MMC interruptions. | Keep meals comparable; log timing, circumference peak, stool, pain, walking, and caffeine/tea timing. Improvement is useful but not diagnostic proof of SIBO. |
| **Optional 24-hour fast** | Whether complete food absence changes bloating, walking-related distension, stool/urgency, sleep/HR/HRV, cravings, and refeed response. | Optional only; keep away from final repeat labs and treat it as a symptom/motility probe, not a longevity or bleeding-risk intervention. Defer 48-hour and 72-hour fasts until after the clean month because they add lean-mass, sleep, lipid/ApoB, inflammatory/platelet, bowel-output, and refeeding confounding. |
| **Probiotic stop/rechallenge** | Whether daily S. boulardii or a base probiotic earns its place. | One change at a time; avoid stacking multiple products. Use symptom and stool-photo changes, not hope. |
| **Standardized walking route / fitness marker** | Whether fatigue, HR response, and recovery improve with clean-month behavior and iron/BP stability. | Use the same route/time/temperature when practical; treat illness, sleep, and caffeine as confounders. |
| **Periodontal charting and treatment response if disease exists** | Whether oral inflammation is a hidden source of inflammatory tone. | Ask for pocket depths, bleeding on probing, recession/attachment loss, mobility, X-rays if indicated; compare later CRP/ESR/WBC/platelets only if disease was actually found. |

## Parked / low-yield novelty tests

| Test idea | Why parked |
|---|---|
| Broad tumor markers | Too many false positives; not a coherent screening strategy. CEA history already has colonoscopy context; new markers should be symptom/imaging-directed. |
| Broad autoimmune panels | Old ANA/ANCA/RF/anti-CCP were negative; repeat only if symptoms point to a defined autoimmune question. |
| Broad microbiome sequencing / fecal SCFA / TMAO chasing | Not decision-grade for this case; current KB already rejects it as a core next step. |
| Broad CHIP/myeloid NGS without stepwise workup | Premature before repeat CBC/differential, smear, reactive-cause cleanup, and focused JAK2/CALR/MPL/hematology logic. |
| Full-body CT | Incidentaloma/radiation burden; no net-benefit screening rationale. |
| Routine cortisol/testosterone/DHEA “optimization” panel | Not tied to a current decision branch. Use only if symptoms create a real endocrine question. |

## Practical next sequence

1. Finish the current 30-day protocol and day-30/31 repeat dataset.
2. Start/complete the 7-day BP profile as soon as a validated cuff is available.
3. Book baseline echo and confirm CAC/CCTA route details; do not pay for vague “coronary screening” without knowing what is reported.
4. If adding one cheap blood clarification soon, make it **true SPEP / Protein Electrophoresis** because the previous electrophoresis result was the wrong type for IgA.
5. After repeat CBC/stool/iron results, decide whether smear/JAK2, GI-source workup, or PSA/free-PSA branch is actually triggered.
6. Add uACR ± cystatin C when convenient as a durable vascular/kidney baseline, especially before contrast imaging or if BP is elevated.

## Research trace

- Research date: 2026-05-04; fasting branch reviewed and integrated 2026-05-10.
- Research mode: clinical decision synthesis + local-lab logistics.
- Context checked: refreshed cloud doc; current research queue; KB index; BP, post-30-day exam, day-0 Biomed testing, SIBO/MMC, thrombocytosis, ferritin/iron, CT/CAC/CCTA, Phnom Penh access, and elevated-IgA owners.
- Biomed tariff checked live: SPEP/protein electrophoresis $25; immunofixation $80; FLC kappa/lambda $130; JAK2 V617F $150; Cystatin C $15; NT-proBNP $40; Free PSA $15; PSA Total $10; TPO Ab $15; anti-thyroglobulin $16.25; Albumin Micro/Urine $10; Creatinine/Urine $2.50; FOB $7.50; Stool Direct Exam $2; no public tTG/DGP/EMA/HLA-DQ2/DQ8, CALR/MPL, FIT, SIBO breath, SeHCAT/C4/FGF19/fecal bile-acid rows found.
- Evidence anchors: ESC 2024 BP guideline (PMID: 39210715); AHA home-BP technique/policy guidance; EAS Lp(a) consensus for ASCVD/aortic stenosis (PMID: 36036785); Miami Heart Study Lp(a)/CCTA/CAC=0 signal (PMID: 39012945); AGA bloating/distension CPU (PMID: 37452811); CAP 2024 monoclonal-gammopathy laboratory guidance; KDIGO 2024 CKD evaluation/risk framing; AUA/SUO prostate early-detection repeat-PSA principle; ET/thrombocytosis review (PMID: 38269572); fasting branch anchors: prolonged fasting review (PMID: 37377031), intermittent-fasting RCT meta-analysis (PMID: 40533200), 48h cognition/mood studies (PMIDs: 28025637, 32504694), 72h metabolic studies (PMIDs: 30183740, 12388154), supervised fasting safety cohorts (PMIDs: 29458369, 30601864), and prolonged fasting inflammation/platelet activation signal (PMID: 40268190).
- Integration decision: new standalone planning topic justified because the question recurs across domains and needs a ranked “new personal information” filter rather than another organ-specific test list.

```


---

## Original `planned-blood-tests.md`

```markdown
---
abstract: >-
  The 2026-04-26/27 Biomed day-0 testing is now updated with the Vietnam add-ons:
  fasting insulin/glucose, reticulocyte, fibrinogen, urine analysis, IgG, IgM,
  and hemoglobin electrophoresis are in. IgG and IgM are normal, which makes
  the IgA abnormality more isolated; the missing distinction is that hemoglobin
  electrophoresis is not SPEP/protein electrophoresis, so the monoclonal-vs-polyclonal
  IgA pattern is not yet fully characterized.
---

# Biomed Visit Record — Day-0 Testing Completed (2026-04-26/27)

This is the day-0 lab-order record only. The behavioral protocol, tracking rules, and day-30 interpretation map live in the separate [30-Day Experiment](#sec-thirty-day-experiment) article.

**Status:** blood draw completed on 2026-04-26 shortly after the 14:00 Cambodia experiment start. Pages 1-2 plus the later Vietnam add-ons now show normal reticulocyte, high-normal fibrinogen, favorable fasting insulin/glucose, clean urine, normal IgG/IgM, and normal hemoglobin electrophoresis. Biomed's tariff has both **Electrophoresis-Hemoglobin** and **Electrophoresis-Protein / Protein Electrophoresis** at $25, plus **Immunofixation Electrophoresis** at $80. The returned Hb A / Hb A2 report confirms the hemoglobin version was performed, so the intended serum protein electrophoresis (SPEP) was probably missed at ordering rather than completed under another name.

Context: the 2026-04-19/20 results are close enough to use as the blood/stool baseline for most markers. Do not waste money repeating markers that were just measured unless there is a specific reason. The tests below are the useful non-April additions for the 30-day experiment and the elevated-IgA branch.

## Ordered tests and results for the day-0 round

The ordered day-0 items are now resulted. The only important caveat is the protein-electrophoresis mismatch already captured in the table below.

| Test | Biomed name | Price | Result / current interpretation |
|---|---:|---:|---|
| Reticulocyte | Reticulocyte | $1.25 | **1.0%** (ref 0.5-2.0): normal marrow-response baseline; no acute reticulocyte surge suggesting major active blood loss at this snapshot. |
| Fibrinogen | Fibrinogen | $5.00 | **3.7 g/L** (ref 2.00-4.00), prior 3.5 on 2025-10-03: high-normal, still useful for the platelet/WBC/reactive-thrombotic comparison after the clean month. |
| Fasting glucose | Glucose (FBS/Glycémie) | $1.00 | **99 mg/dL** (~5.49 mmol/L; ref 74-109 mg/dL): high-normal fasting glucose. |
| Fasting insulin | Insulin (Fasting) | $12.00 | **4.4 µIU/mL** (ref 2.6-24.9): low-normal; with glucose 99 gives **HOMA-IR ~1.08**, supporting good insulin sensitivity rather than insulin resistance. |
| IgG | IgG | $10.00 | **1299 mg/dL** (ref 540-1822): normal. This argues against broad IgG hypergammaglobulinemia and makes the high IgA more isolated. |
| IgM | IgM | $10.00 | **72.50 mg/dL** (ref 22-240): normal. No IgM-driven inflammatory or lymphoplasmacytic pattern from this result. |
| Protein Electrophoresis | Electrophoresis-Protein / Protein Electrophoresis | $25.00 | **Likely not performed.** Biomed also lists Electrophoresis-Hemoglobin at $25; the returned Hb A/Hb A2 page confirms the hemoglobin version, not SPEP. |
| Hemoglobin electrophoresis | Electrophoresis | — | **Normal profile:** Hb A 97.2% (ref 96.8-97.8), Hb A2 2.8% (ref 2.2-3.2). This argues against beta-thalassemia trait as a hidden explanation for CBC/iron patterns. |
| Urine Analysis Complete | Urine Analysis Complete | $2.00 | Clean: no protein, glucose, ketones, blood, nitrite, bacteria, casts, crystals, or yeast; pH 6.0, specific gravity 1.015, urine WBC 5 and RBC 3 per field within range. |

**Core total ordered: $66.25**

Optional only if still trying to preserve a late paired baseline:

| Test | Biomed name | Price | Why / skip rule |
|---|---:|---:|---|
| Homocysteine | Homocysteine total | $25.00 | Previously upper-normal; alcohol abstinence, B-vitamin status, vegetarian diet, and iron status can all affect interpretation. Not recorded in April. |
| Folate | Folate (Folic Acid) | $16.25 | Makes homocysteine interpretable; not recorded in April. More useful if homocysteine is included. |

**Full total with optional homocysteine + folate: $107.50**

## Already measured in April — do not repeat at the next visit by default

| Test | April result / status | Use as baseline? |
|---|---:|---|
| CBC/Hg | 2026-04-19: Hb 14.4, WBC 13.1, platelets 494 | Yes |
| Ferritin | 2026-04-19: 54.01 | Yes |
| Iron | 2026-04-19: 11.64 | Yes |
| TIBC | 2026-04-19: 61.07 | Yes |
| CRP | 2026-04-19: 2.91 | Yes |
| ESR | 2026-04-19: 20 | Yes |
| Transferrin | 2026-04-20: 284.4 | Yes |
| Calprotectin / stool | 2026-04-20: 13.3 | Yes |
| Stool occult blood / stool RBC | 2026-04-19: positive / present | Yes |
| Gastrin | 2026-04-20: 30.7, normal | Yes |
| HbA1c | 2026-04-19: 5.1% | Yes |
| Lipids / ApoB | 2026-04-19/20: LDL 2.04, HDL 1.99, TG 1.29, ApoB 66.31 | Yes |
| Vitamin B12 / D / Magnesium | 2026-04-19: B12 231, D 105.1, Mg 0.86 | Yes |

Iron 11.64 + TIBC 61.07 already imply TSAT around 19%, so do not order separate Transferrin Saturation at the next visit unless a clinician specifically wants the lab-reported value.

## What Protein Electrophoresis is doing here

Serum protein electrophoresis (SPEP) separates blood proteins into bands. The practical reason to order it here is the new high IgA: it helps distinguish a broad reactive/inflammatory immunoglobulin pattern from a narrow monoclonal-looking pattern that would deserve follow-up testing such as immunofixation or hematology interpretation.

The new page labelled “Electrophoresis” is **hemoglobin electrophoresis**, not SPEP. This now looks like a plausible order-selection mismatch: Biomed lists both Electrophoresis-Hemoglobin and Electrophoresis-Protein/Protein Electrophoresis at $25. Hb A/Hb A2 being normal is useful for excluding beta-thalassemia trait, but it does not answer the IgA band-pattern question.

This is not because a serious plasma-cell disorder is the most likely explanation. It is a cheap-ish one-time clarification test because IgA is clearly high and normal IgG/IgM alone cannot show the band pattern. The full staged logic now lives in [Elevated IgA Workup](#sec-elevated-iga).

Do **not** add Immunofixation Electrophoresis ($80) or FLC Kappa & Lambda ($130) by default at the next blood visit. Those are second-line if SPEP/urine/basic labs or clinical red flags make a monoclonal-gammopathy branch more plausible.

## Next-result analysis framework

Use this as the remaining interpretation framework. IgG/IgM have landed normal; the unresolved IgA branch is whether a true SPEP/protein electrophoresis result exists and whether it is non-suspicious.

| Result cluster | Meaning | Action |
|---|---|---|
| IgG/IgM normal and SPEP polyclonal/non-suspicious | IgA elevation is more likely reactive/inflammatory than monoclonal | No automatic immunofixation/FLC spend; repeat immunoglobulins only if IgA rises, total protein/globulin changes, urine/protein abnormalities appear, or symptoms develop |
| SPEP shows narrow/suspicious band or unclear monoclonal language | Monoclonal branch opens | Add immunofixation and serum free light chains; consider hematology-style interpretation |
| Urine remains clean | Plasma-cell/kidney red-flag branch weakens | Keep focus on reactive/inflammatory and trend follow-up |
| CBC: WBC and platelets fall after the clean month | Reactive exposure/inflammation explanation strengthens | Continue trend monitoring; no reflex molecular testing |
| CBC: platelets >=450 and/or WBC remains high | Reactive-only explanation weakens | CBC differential + smear; iron panel/CRP/ESR/fibrinogen context; JAK2/CALR/MPL if still unexplained |
| Ferritin/TSAT/Hb stable or improved and stool blood clears | Occult-loss branch cools | Continue planned monitoring; avoid broad GI escalation unless symptoms/alarm signs appear |
| Ferritin/TSAT/Hb worsens or stool blood persists | Bleeding-source branch remains active | Repeat stool logic and GI-source discussion; do not dismiss because calprotectin is normal |
| Fibrinogen falls with WBC/platelets | Reactive/inflammatory-thrombotic tone improving | Good experiment signal, but not proof of low cardiovascular risk |
| Fibrinogen stays high-normal/rises with WBC/platelets | Persistent inflammatory/thrombotic tone | Revisit inflammatory-thrombotic and thrombocytosis pathways |
| PSA remains near/above 3.0 or rises on standardized repeat | Urology branch persists | Add/interpret free PSA if not done; avoid infection/ejaculation/cycling/prostate-irritation confounders |
| PSA falls toward prior baseline | Transient PSA fluctuation more likely | Monitor trend rather than escalate from one spike |

**Do not pre-order a Round-2 blood panel by habit.** Add tests only when the result branch needs them: immunofixation/FLC for suspicious SPEP, smear/molecular testing for persistent unexplained platelet/WBC abnormalities, free/total PSA for persistent PSA concern, and GI/stool follow-up for persistent blood or iron drift.

## End-of-experiment checks

The day-30 repeat panel and interpretation map live in [30-Day Experiment](#sec-thirty-day-experiment). Keep this page focused on what to order at the next Biomed blood visit.

For paired interpretation, repeat at day 30 the experiment-specific baseline markers taken now: reticulocyte, fibrinogen, fasting glucose, and fasting insulin. Do not repeat the IgA clarification block by default; IgG/IgM and urine are now reassuring one-time clarifiers, while SPEP/protein electrophoresis remains useful only if it was not actually performed or if a clinician wants formal band-pattern documentation.

IgA side-quest interpretation still belongs here:

| Pattern | Meaning |
|---|---|
| Normal IgG/IgM + clean urine, but no SPEP | Reassuring, but not a complete monoclonal-vs-polyclonal IgA pattern check. |
| SPEP looks polyclonal/non-suspicious | IgA more likely reactive/inflammatory. |
| SPEP looks suspicious | Escalate the IgA branch to immunofixation / hematology-style interpretation. |

```